A Study of RXDX-106, an Oral Immunomodulatory TYRO3, AXL, and MER (TAM) Tyrosine Kinase Inhibitor, in Patients With Locally Advanced or Metastatic Solid Tumors

Trial Profile

A Study of RXDX-106, an Oral Immunomodulatory TYRO3, AXL, and MER (TAM) Tyrosine Kinase Inhibitor, in Patients With Locally Advanced or Metastatic Solid Tumors

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Mar 2018

At a glance

  • Drugs RXDX-106 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Acronyms TITAN
  • Most Recent Events

    • 02 Mar 2018 Status changed from planning to not yet recruiting.
    • 03 Jan 2018 New trial record
    • 29 Dec 2017 According to an Ignyta media release, the US FDA has cleared the IND application for RXDX-106 in patients with solid tumors. This trial is expected to begin in early 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top